Investigation of Incentives to Promote Medication Adherence Among HIV-Infected Youth on Antiretroviral Therapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- HIV
- Sponsor
- St. Jude Children's Research Hospital
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Pharmacy pill count
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
Medication adherence is one of the most salient predictors of patient outcomes in the era following development of effective treatment for HIV infection. Evolving strategies to improve adherence, specifically incentive interventions and real-time medication monitoring, have shown some success in limited studies. Further investigation into incentive interventions for HIV-infected adolescents with poor medication adherence is necessary.
Detailed Description
PRIMARY OBJECTIVE: * To describe the effects of a novel incentive intervention model on HIV-infected youths' patterns of antiretroviral medication adherence. SECONDARY OBJECTIVES: * To evaluate the feasibility of an outpatient incentive intervention model. * To assess participant satisfaction with the incentive intervention model. * To evaluate the effect of an outpatient incentive intervention model on targeted health behaviors (numbers of missed appointments and STI diagnoses). * To measure the effect of the incentive intervention on HIV viral load and CD4+ count. * To determine the overall and per patient cost of the incentive intervention model. * To describe associations between adherence measures: real-time medication monitor data, pharmacy pill count, pharmacy prescription pick-up data, medication possession ratio, and self-report. Upon enrollment, participants will receive education and a real-time medication monitor. Participants will be followed monthly in the clinic and will be prescribed thirty-day supplies of medication. During weeks 1-4 participants will establish a baseline with the real-time medication monitor. During weeks 5-28, participants will receive remote incentives based on their level of medication adherence as measured by the real-time medication monitor. Additional lottery-style incentives will occur at regular follow-up visits. No incentives will be applied during weeks 29-48. Participants will complete the protocol at the week 48 visit.
Investigators
Eligibility Criteria
Inclusion Criteria
- •≥16 and ≤ 24 years old
- •Documented diagnosis of HIV
- •Adolescent is aware of his/her HIV diagnosis
- •Adolescent understands either written or spoken English.
- •Adolescent is willing and able to provide informed consent or assent.
- •Adolescent has access to a phone and the internet at the time of enrollment.
- •Adolescent meets the definition of inadequate ARV adherence, which is any of the following in the previous 12 months:
- •\< 80% adherent to any ARV by pharmacy pill count
- •≥ 7 days delay in scheduled ARV prescription pick-up
- •Detectable viral load after being on ARVs for at least 12 weeks
Exclusion Criteria
- •Adolescent has a documented diagnosis of mental retardation or a significant motor or sensory impairment that would preclude participation.
- •Adolescent has a documented acute psychiatric illness, including suicidal ideation, homicidal ideation or active psychosis.
- •Adolescent was diagnosed with HIV in the previous 6 months.
- •Adolescent has a planned transition to alternative care setting prior to study completion (e.g. relocation, pregnancy or planned pregnancy, transition to adult care).
- •Concurrent enrollment on a research study with an intervention targeted at increasing adherence to antiretroviral regimens.
Outcomes
Primary Outcomes
Pharmacy pill count
Time Frame: Monthly from 6 months prior to study start through week 48
Pharmacy pill count data is collected at each participant encounter, approximately once per month.
Percentage of dosages taken within 2 hours of prescribed time per month
Time Frame: Monthly through week 48
Data collected by a real-time medication monitor that records pillbox opening times.
Secondary Outcomes
- Feasibility - Device replacement rate(End of study (week 48))
- Feasibility - Accrual percentage(End of study (week 48))
- Feasibility - Participant reported device concerns(End of study (week 48))
- Feasibility - Adverse effects of incentives(End of study (week 48))
- Effect of incentives on STI rates(Enrollment (week 0) and end of study (week 48))
- Change in biological parameters(At weeks 0, 12, 24, 36 and 48)
- Feasibility - Drop out rate(End of study (week 48))
- Feasibility - Contact failure rate(End of study (week 48))
- Association between adherence measures(End of study (week 48))
- Feasibility - Staff hours per week(End of study (week 48))
- Percentage of participants who are satisfied with the incentive intervention(Enrollment (week 0) and end of study (week 48))
- Effect of incentives on missed appointment rate(Enrollment (week 0) and end of study (week 48))
- Overall cost of incentive intervention(End of study (week 48))